THE SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR DAPAGLIFLOZIN EXERTS CARDIOPROTECTIVE EFFECTS AGAINST DOXORUBICIN AND TRASTUZUMAB TOXICITY THROUGH TLR4/MYD88/NF-KB SIGNALING AND NLRP3 INFLAMMASOME PATHWAY

The clinical trial “DECLARE-TIMI 58” demonstrated that Dapagliflozin, a Sodium glucose cotransporter 2 inhibitor, reduces the composite end point of cardiovascular death/hospitalization for heart failure in a broad population of patients with type 2 diabetes mellitus. We aimed to study if